These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 17036864)

  • 1. [Defining trials of medicinal products according to the revised Dutch Medical Research in Human Subjects Act (WMO)].
    Vos EJ; Huitema AD
    Ned Tijdschr Geneeskd; 2006 Sep; 150(38):2104-7. PubMed ID: 17036864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Medical research in children: the pros and cons of extending the legal boundaries].
    Visser HK
    Ned Tijdschr Geneeskd; 2010; 154():A2395. PubMed ID: 20858300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [European guideline for the quality of non-commercial clinical trials: elegant implementation in the Netherlands via the amended Dutch Medical Research Involving Human Subjects Act].
    Cohen AF
    Ned Tijdschr Geneeskd; 2003 Aug; 147(31):1493-5. PubMed ID: 12924078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishing pan-European clinical trials: regulatory compliance and other practical considerations.
    Grienenberger A
    J Biolaw Bus; 2004; 7(4):58-63. PubMed ID: 15675097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploratory clinical trials: implementation modes & guidelines, scope and regulatory framework.
    Francillon A; Pickering G; Belorgey C
    Therapie; 2009; 64(3):149-59. PubMed ID: 19671427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The development of good clinical practice in the EEC and in Germany.
    Anhalt E
    Methods Find Exp Clin Pharmacol; 1993 May; 15(4):217-22. PubMed ID: 8361258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical trials on medical products for human use in the case of acutely incapacitated patients within the fields of neurology and neurosurgery; implications of the new European legislation].
    Kompanje EJ; Maas AI; Dippel DW
    Ned Tijdschr Geneeskd; 2003 Aug; 147(33):1585-9. PubMed ID: 12951727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stem cell transplantation in children: how to design a new study.
    Corbacioglu S;
    Bone Marrow Transplant; 2008 Jun; 41 Suppl 2():S30-4. PubMed ID: 18545241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Trials Legislation - preparing for the revision of the European Directive Scheduled for 2011.
    Bilbault P; Belorgey C; Zannad F; Golinelli D; Pletan Y;
    Therapie; 2010; 65(4):301-8, 291-9. PubMed ID: 20854751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Doctor-initiated clinical trials and the revised pharmaceutical affairs law].
    Takano T; Saijo N
    Gan To Kagaku Ryoho; 2003 Oct; 30(10):1391-7. PubMed ID: 14584270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical treatment of echinococcosis under the guidance of Good Clinical Practice (GCP/ICH).
    Kern P
    Parasitol Int; 2006; 55 Suppl():S273-82. PubMed ID: 16338164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory aspects for translating gene therapy research into the clinic.
    Laurencot CM; Ruppel S
    Methods Mol Biol; 2009; 542():397-421. PubMed ID: 19565915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The conduct of clinical trials for medicinal products in europe in the light of the European clinical trials directive. Review of regulatory and practical aspects in the different countries.
    Dubray C; Maillere P; Spriet A;
    Therapie; 2007; 62(3):193-7, 199-202. PubMed ID: 17803885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The scope and requirements related to preclinical and clinical studies of a new medicinal product, including biotechnological and biosimilar products.
    Brodniewicz-Proba T
    Acta Pol Pharm; 2008; 65(6):641-5. PubMed ID: 19172845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The regulatory system in europe with special emphasis on allergen products.
    Lorenz AR; Luttkopf D; Seitz R; Vieths S
    Int Arch Allergy Immunol; 2008; 147(4):263-75. PubMed ID: 18648190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relatively good safety in Swedish phase I trials. A survey of studies reported to the Medical Products Agency during 3 years].
    Glazer A; Hedenmalm K
    Lakartidningen; 2008 Sep 10-16; 105(37):2482-4. PubMed ID: 19006863
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical drug research in children: current international guidelines. Committee for Proprietary Medicinal Products].
    Ruys-Dudok van Heel I; Cohen AF; Wit JM; van der Heijden AJ; van den Anker JN; van Meurs AH
    Ned Tijdschr Geneeskd; 1998 Jan; 142(1):6-9. PubMed ID: 9556981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ethical issues of clinical trials in children: a European perspective.
    Sammons H
    Arch Dis Child; 2009 Jun; 94(6):474-7. PubMed ID: 19208673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New perspective and new challenges in clinical trial regulation in Italy.
    Tomino C
    Ann Ist Super Sanita; 2011; 47(1):19-21. PubMed ID: 21430333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.